(A) Representative Western blot for the specified proteins in the sWAT of control or ad-Insig1 mice exposed to dox for 12 hours or 2 weeks. (B and C) Densitometric quantification of Western blots for (B) pS6^Ser240/244 or (C) pAKT^Thr308 and pAKT^ser473 following the indicated durations of dox exposure (n = 3–5). (D) Control and ad-Insig1 mice were injected with rapamycin (rapa;4 mg/kg) every second day for 2 weeks while on dox-containing chow. Lipogenic gene expression was determined in sWAT following the 2-week treatment (n = 5). (E) Representative Western blot and densitometry of sWAT FASN and ACC protein levels in control or ad-Insig1 mice with or without rapa (n = 5–7). (F) sWAT and eWAT weights after 2 weeks treatment with both dox and rapa (n = 5–6). (G) Triglyceride clearance test performed following 3 weeks of dox and rapa treatment (n = 6–7). (H) Oral glucose tolerance test conducted following 2 weeks of dox and rapa treatment (n = 6). (I) Insulin measurements during oral glucose tolerance (n = 6). (J) H&E stain of pancreatic islet (arrow). Original magnification, ×20. All data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by 2-tailed Student’s t test (bar graphs) or 2-way ANOVA (systemic assays). The Tukey correction was used for multiple comparisons. In all cases, for a given condition, representative Western blot images are from the same sample, although the target proteins may have been probed on separate membranes to facilitate clear visualization. All densitometry was conducted on samples run on the same gel.